Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India
===========================================================================================================================================

* Ameet Dravid
* Reema Kashiva
* Zafer Khan
* Balasaheb Bande
* Danish Memon
* Aparna Kodre
* Prashant Potdar
* Milind Mane
* Asir Tamboli
* Vishal Pawar
* Dattatraya Patil
* Debashis Banerjee
* Kailas Bhoite
* Akshay Shinde
* Reshma Pharande
* Suraj Kalyani
* Prathamesh Raut
* Madhura Bapte
* Charlotte Saldanha
* Dinesh Chandak
* Fouzia Ajani
* Anshul Mehta
* M Sateesh Reddy
* Krushnadas Bhayani
* S S Laxmi
* P D Vishnu
* Shipra Srivastava
* Shubham Khandelwal
* Sailee More
* Atif Shakeel
* Mohit Pawar
* Pranava Nande
* Amol Harshe
* Sagar Kadam
* Sudhir Hallikar
* Nudrat Kamal
* Danish Andrabi
* Sachin Bodhale
* Akshay Raut
* Pushkar Gawande
* Ankush Bhandari
* Nilesh Wasmatkar
* Adnanali Sarkar
* Sangeeta Chandrashekhar
* Pallavi Butiyani
* Geetanjali Akhade
* Aditi Abnave
* Chandrashekhar Raman
* Siraj Basade
* Uma Mahajan
* Gaurav Joshi
* Dilip Mane

## Abstract

**Background** The second COVID-19 wave in India, triggered by the Delta variant,has been associated with an unprecedented increase in cases of COVID-19 associated Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM).The primary reason appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia, uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune dysfunction.

**Methods** This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, Western India between 1st April 2020 and 1st August 2021 to identify patients admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM. Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU) admission. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk estimation.

**Results** 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal (disseminated) mucormycosis). Median age of the cohort was 52(IQR: 41,61) years and it included 20.3% females. Median duration from first positive COVID-19 RT PCR test to diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30% being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56% patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy) while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority of the patients were treated with a combination of surgical debridement(94%), intravenous Amphotericin B(91%) and concomitant oral Posoconazole therapy(95.4%). 74.6% patients were discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk analysis, CT severity score during COVID-19 admission ≥18 (p=0.017), presence of orbital symptoms(p=0.002), presence of diabetic ketoacidosis(p=0.011) and cerebral involvement by Mucor(p=0.0004) were associated with increased risk of death. Duration of Amphotericin B therapy of ≥ 21 days was associated with statistically significant reduction in mortality(p=0.002).

**Conclusions** CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal infection which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases.

## Introduction

In December 2019, Wuhan city, the capital of Hubei province in China, became the centre of an outbreak of viral pneumonia. By Jan 7, 2020, scientists had isolated a novel RNA, beta coronavirus from these patients. It was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to its sequence homology with SARS-COV-1 [1]. The disease caused by SARS-COV-2 was later designated coronavirus disease 2019 (COVID-19) in February 2020, by World health organization (WHO) [2]. COVID-19 spread rapidly worldwide and India was no exception. By 1st August 2021, there have been more than 300 million infections and 0.4 million deaths due to COVID-19 in India [3]. With COVID-19, the incidence of secondary bacterial or fungal infections is 8%, with aspergillosis and candida being the most common fungi reported [4,5]. The second COVID wave in India (March 2021 – May 2021), triggered by the Delta variant, has also been associated with an unprecedented increase in the cases of COVID-19 associated Mucormycosis (CAM) [6,7]. Globally, the prevalence of mucormycosis varies from 0.005 to 1.7 per million population, while its prevalence is nearly 80 times higher (0.14 per 1000) in India as per a recent estimate of year 2019-2020 [7-9]. Thus, India already had the highest cases of mucormycosis in the world and the incidence increased exponentially during the second COVID wave. As of August 1st, 2021, 45,374 cases of CAM have been reported in India [6].

CAM is an uncommon, rapidly progressive, angio-invasive, commonly fatal, opportunistic fungal infection [9]. Unusual alignment of multiple risk factors could be associated with sudden spurt of CAM in India [10]. Dysregulated immune response in COVID-19 characterized by exuberant activation of innate immune system, elevation in systemic inflammatory markers (C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and D-dimer), aberrant pro-inflammatory cytokine secretion (Interleukin – 6 (IL-6), soluble IL-2 receptor [IL-2R], IL-10, TNF-α) by alveolar macrophages and depleted adaptive immune response (decline in CD4+ T cell, CD8+ T cell, Natural killer cell and decreased Interferon Gamma (IFN-γ) expression in CD4+ T cells) could be one of the factors predisposing individuals to CAM [11,12]. In these patients, the activation of antiviral immunity to SARS-CoV-2 may, paradoxically, potentiate an inflammatory phenotype and thus may favor secondary infections. In addition, India has the second largest population with diabetes mellitus (DM) in the world (77 million people with diabetes, with a nationwide prevalence of 7.3 %.)[13, 14]. SARS-CoV-2 has been shown to affect the beta cells of the pancreas, resulting in metabolic derangement, possibly causing diabetes mellitus [15]. Uncontrolled DM is a risk factor for both, COVID-19 and Mucormycosis. Steroids, namely Dexamethasone and Methylprednisolone have been extensively used to resolve hyperinflammation and inflammatory lung damage in severe COVID-19 [16-18]. But use of steroids can cause hyperglycemia, suppression of several polymorphonuclear (PMN) leucocyte functions, impairment of phagocytosis by resident macrophages, depletion of T cell immunity [10] and increase risk of Mucormycosis. Indiscriminate use of steroids in patients with mild or asymptomatic COVID-19 can be counter-productive and make the person susceptible to opportunistic fungi [19]. Use of immunomodulator therapy like Tocilizumab (TCZ, IL-6 receptor inhibitor) in combination with steroids for Cytokine release syndrome (CRS, cytokine storm) could further aggravate immunosuppression and facilitate breakthrough fungal infection [20]. Thus, the primary reason for this sudden increase in CAM in India appears to be germination of Mucorales spores in an ideal environment of low oxygen (hypoxia), high glucose (diabetes mellitus, new onset hyperglycemia, impaired fasting glucose or steroid-induced hyperglycemia), acidic environment[10] (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (hyper-ferritinemia characteristic of COVID-19 leading to excess intracellular iron that generates reactive oxygen species and resultant death of cells with acidosis facilitating free iron release for mucor germination) [21,22] and immune dysfunction (mediated by Delta variant of SARS COV-2, steroid therapy or background co-morbidities).

The most common form of Mucormycosis seen in India during the COVID-19 pandemic was the Rhino-orbito-cerebral (ROCM) one but cases of pulmonary [7,23] or disseminated mucormycosis [24] have also been reported. Suspected ROCM requires urgent intervention, because of the often rapidly progressive and destructive nature of the infection. Delayed initiation of therapy is associated with increased mortality [25,26]. Despite treatment, case-fatality rates due to mucormycosis during the pre-COVID-19 pandemic era were already high, ranging from 32% to 70%, according to organ involvement [25,26]. However, in SARS-CoV-2 infection, the mortality maybe even higher. Maximizing survival rates requires rapid diagnostic and therapeutic intervention, including immediate involvement of a multidisciplinary medical, surgical, radiological, and laboratory-based team. Multiple case reports [27-50] and retrospective cohort studies [7, 51-61] of CAM from India and other countries have already been published. However, detailed epidemiology, risk factor analysis, surgical and medical treatment administered, outcomes and complications (especially long-term complications) developing in these patients has been scarcely reported [7,52,57]. In addition, lack of imaging modalities in rural areas of India, inability to identify early symptoms by general practitioners, shortage of antifungal drugs (especially Liposomal Amphotericin B) during second COVID wave and inadequate number of specialists to perform complex endoscopic, orbital and skull base surgeries [7,10] posed a serious challenge in tackling rising ROCM cases in India and led to a high mortality in certain cohort studies [7,52]. As a result, we planned this retrospective observational cohort study aimed at understanding the epidemiology, clinical presentation, outcomes and long-term complications in patients with CAM admitted at our tertiary level hospital in Pune, Western India during the COVID-19 pandemic.

## Methods

### Study Setting

This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, Western India. NHRC is a tertiary level private hospital designated for clinical management of COVID-19 patients and management of post COVID complications since 23rd March 2020. Pune is located in the state of Maharashtra, Western India and was one of the epicenters of COVID-19 epidemic in India. As of 1st August 2021, Maharashtra state has reported more than 6.3 million cases of COVID-19 and more than 133,000 deaths [3]. Till 1st August 2021, NHRC has admitted 5439 COVID-19 patients with 391 deaths. Maharashtra state has also reported more than 5000 cases of COVID-19 associated Mucormycosis (CAM) till 1st August 2021[6].

NHRC provides clinical care, diagnostic and treatment services to patients at a subsidized cost. Data of all hospitalized patients is entered into an electronic database (Lifeline electronic database, Manorama infosystems, Kolhapur, India).

### Study Population

Patients were eligible for inclusion in this analysis if they were admitted to NHRC between 1st April 2020 and 1st August 2021 and were diagnosed with COVID-19 associated Mucormycosis (CAM). COVID-19 diagnosis was made in patients who tested positive for SARS COV 2 RNA in respiratory specimens by reverse transcription PCR (RT-PCR) or a positive rapid antigen test. Mucormycosis was identified in patients having compatible clinical and radiologic manifestations and demonstration of fungi in the tissue or sterile body fluids by either direct microscopic visualization of broad ribbon-like aseptate hyphae (potassium hydroxide (KOH) mount or Calcofluor stain), culture isolation of Mucorales (Sabouraud dextrose agar) or Histopathology examination of affected tissue showing Mucor species (Hematoxylin and eosin, periodic acid Schiff, or Gomori methenamine silver stain) [9]. CAM was defined as development of Mucormycosis within 3 months of diagnosis of COVID-19.

Data was obtained from electronic health record of each individual admitted for treatment of CAM in NHRC by manual abstraction. It included hospitalization dates, demographics, co-morbidities, severity of associated COVID-19 illness, treatment received for COVID-19 including steroids and immunomodulator therapy, presenting symptoms of Mucormycosis, clinical examination data, anatomic site of involvement, diagnostic modalities including microscopy, culture, or histopathology, laboratory investigation data (including inflammatory markers), microbiology reports, imaging reports (High resolution computerized tomography scan of chest, paranasal sinuses and brain (HRCT chest, CT PNS and CT brain)), treatment details, including antifungal drug therapy and surgical debridement, data on use of supplemental oxygen, mechanical ventilation and hospitalization outcomes. Mild COVID was defined as individuals who have various signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnea, or abnormal chest imaging [62]. Moderate disease was defined as patients who show evidence of lower respiratory disease during clinical assessment or imaging and who have oxygen saturation (SpO2) 90 to ≤ 93% on room air. Severe COVID was defined as SpO2 < 90% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg, respiratory frequency > 30 breaths/min or lung infiltrates >50% [62]. Critical COVID was defined as presentation with respiratory failure, septic shock, and/or multiple organ dysfunction. For all patients diagnosed with CAM, we also scrutinized inpatient case files until hospital discharge, death, or 1st September 2021—the date on which the database was locked—whichever happened first. Systemic complications developing in patients during hospital admission were also noted. All patients who died due to CAM during hospital admission were identified and a death audit to look for complications and cause of death was undertaken. For patients who left the hospital against medical advice, we considered a worst-case scenario for mortality analysis and assumed the patients died. All patients who recovered, got discharged from NHRC and had outpatient follow-up at 15, 30 and 90 days after discharge were identified. Their outpatient follow-up visits were traced from electronic database to look for delayed complications.

### Management of Mucormycosis at NHRC

NHRC protocol for management of Mucormycosis has been developed after careful consideration of current global and national guidelines [63,64]. As per the protocol, early, radical, surgical debridement of affected site in addition to combination systemic antifungal therapy was utilized for treatment.

### Surgical management

Functional endoscopic paranasal sinus surgery (FESS) with debridement of necrosed and diseased sinus tissue and orbital decompression was the most common surgical procedure performed in patients with ROCM. All efforts were made to preserve the eye for as long as possible in view of role of eye to not only provide vision but also its removal causing significant psycho-social problems to patient. In patients with total blindness, proptosis, fixed pupil and eyeball, imaging evidence of orbital involvement by Mucor (globe/muscles/fat) and/or intracranial spread (superior orbital fissure/inferior orbital fissure involvement), surgical exenteration of the eye was performed [65]. Surgical exenteration of the eye with debridement of orbital cavity was performed in consultation with Department of Otorhinolaryngology and Ophthalmology. Partial or total maxillectomy was performed in patients with evidence of osteomyelitis of maxilla or alveolar arch. Neurosurgery was performed in case of intracranial spread of disease with involvement of skull base or formation of basi-frontal lobe brain abscess.

### Medical management

Combination therapy of Liposomal Amphotericin B (LAmB) and Oral Triazole (predominantly oral Posaconazole) was the most common medical treatment offered to all patients with CAM. LAmB was initiated at the dose of 5 mg/kg. The dose was increased to 10 mg/kg in case of intracranial spread [63,64]. In the scenario of shortage of LAmB due to surge in CAM cases or non affordability of patient, other formulations of Amphotericin B (Amphotericin B lipid complex (5 mg/kg), Amphotericin B lipid emulsion (5 mg/kg) and Amphotericin B de-oxycholate (1 mg/kg)) were used for patients. The duration of Amphotericin B treatment was decided depending on the site of involvement (3 weeks for only paranasal sinus involvement, 4 weeks for orbital, lung and disseminated Mucormycosis and 6 weeks for Central nervous system (CNS) Mucormycosis). Oral Posaconazole (delayed release tablets, 300 mg twice a day on Day 1 and then 300 mg once a day) was started along with Amphotericin B treatment and continued after discharge from hospital for a period of 1 to 3 months depending on local control of disease and discretion of Infectious disease physician. In patients with concomitant chronic kidney disease, intravenous Posaconazole or Isavuconazole followed by step-down to oral therapy was treatment of choice. Serum Posaconazole levels were performed to guide dosage during oral therapy.

### Outcomes

Primary endpoint:

1.  Deaths in the cohort due to CAM.

Secondary outcomes:

*   2. Number of patients who had a clinical and radiologic recovery and were discharged from hospital.

*   3. Patients who required mechanical ventilation (noninvasive or invasive) and Intensive care unit (ICU) admission for CAM.

*   4. Incidence of systemic complications (including long-term complications) in patients after starting Amphotericin B therapy. The use of database for clinical research was approved by the institutional review board (IRB) of Noble hospital and Research Centre, Pune, India.

## Statistical Methods

Continuous variables were summarized using median and interquartile range (IQR), while categorical variables were summarized using frequency and percentages. Continuous variables were compared using a Mann Whitney U test. Categorical variables were compared using Chi-square test, Proportion test and Fishers’ exact test. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk analysis. Baseline risk factors included for analysis were age (< 60 years or ≥ 60 years), gender, severity of baseline COVID disease (CT severity index ≥ 18 versus < 18), presence of orbital or central nervous system (CNS) symptoms, presence of diabetic keto-acidosis, presence of intracranial spread (cerebral involvement) and baseline investigations like absolute lymphocyte count (< 1000 versus ≥ 1000 cells/mm3), C reactive protein (≥ 50 versus < 50 mg/L), D-dimer (≥ 252 versus < 252 mcg/mL) and Ferritin (≥ 1000 versus < 1000 mcg/L). Time dependent risk factors included duration of Amphotericin B therapy (< 3 weeks versus ≥ 3 weeks) and development of systemic complications like acute kidney injury, hepatitis, anemia, thrombocytopenia, osteomyelitis and CNS complications (stroke or cerebritis). The p value ≤ 0.05 was considered as statistically significant. All data was analyzed by SPSS version 12.0.

## Results

During the period between 1st April 2020 to 1st August 2021, 59 patients were diagnosed with Mucormycosis at NHRC. Fifty-eight patients were diagnosed to have ROCM while 1 patient was diagnosed to have Renal (disseminated) mucormycosis. Median age of the cohort was 52 (IQR: 41, 61) years and it included 20.3 % (12/59) females. Seventeen (28.8 %) patients were > 60 years of age. Fifty-six (95 %) patients had pre-existing or newly diagnosed co-morbidities. Diabetes mellitus (53/59, 89.8 %) was the most common co-morbidity seen in our cohort. Of these, 15 patients (28.3 %) were newly diagnosed with diabetes during hospital admission for COVID-19. Two patients were diagnosed to have impaired fasting glucose (Fasting blood glucose between 110 and 125 mg/dl). Preexisting co-morbidities observed in patients at admission are enumerated in Table 1. Three patients (5.1%) had no co-morbidities prior to developing CAM.

View this table:
[Table 1:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T1)

Table 1: Epidemiology of COVID-19 admission in Mucormycosis patients

Clinically, 16 patients (27.1%) had mild COVID, 29 (49.2 %) had moderate COVID and 14 patients (23.7%) had severe or critical COVID disease prior to diagnosis of Mucormycosis. All 59 patients underwent High resolution CT (HRCT) imaging of chest (GE Optima, 128 slice CT scanner) during admission for COVID-19 and median CT severity index was 12 (IQR: 8,14.5). CT severity index [66] indicated mild disease (CT severity index: < 8) in 18.6 % (11/59), moderate disease (CT severity index: 8-14) in 56 % (33/59) and severe disease (CT severity index: 15-25) in 25.4 % (15/59) of patients. Treatments given during COVID-19 admission are enumerated in Table 2a and 2b. Remdesivir was prescribed to 67.8 % (40/59), intravenous and/or oral steroids were prescribed to 100 % and Immune-modulator therapy (Tocilizumab - 5, Barcitinib-2, Idofinib-1, Infliximab-2, Bevacizumab - 2 and Itolizumab - 1) was prescribed to 22 % (13/59) patients in our cohort. Methylprednisolone was the commonest prescribed steroid (54 patients, 91.5%, Table 2b). Most commonly prescribed dose of Methylprednisolone was 1-2 mg/kg/day in divided doses for 5 to 10 days [67]. Ten patients (16.9 %) were prescribed 2 different steroids during treatment course for COVID-19. 56 % (33/59) patients were prescribed steroids in the absence of hypoxia (irrational or unscientific steroid use). In 5 (5/54, 9.3%) patients, Methylprednisolone dose of more than 2 mg/kg/day was prescribed for treatment of severe COVID-19 (wrong or excess steroid dose). Eleven patients (18.6%) required ICU admission while 7 (11.9 %) needed noninvasive or invasive ventilation during hospital admission of COVID-19 infection. Thirteen patients (22%) had received COVID vaccination prior to admission (3 patients received 2 vaccine doses and 10 patients received single vaccine dose, Table 1). Five patients (8.5 %) were treated for COVID-19 while in home quarantine and did not require hospital admission. All 5 patients in home quarantine received steroids (irrational or unscientific steroid use) as a part for of their treatment regimen. Median duration of hospital admission for COVID-19 was 9 (IQR: 6, 14) days.

View this table:
[Table 2a:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T2)

Table 2a: Drugs administered during COVID-19 treatment

View this table:
[Table 2b:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T3)

Table 2b: Steroids and Supplemental Oxygen used during COVID-19 treatment

Median duration from first positive COVID-19 RT PCR test to diagnosis of Mucormycosis was 17 (IQR: 12, 22) days. Duration was less than 14 days for 22 (37.3 %, early CAM) patients while it was > 14 days for 37 (62.7 %, late CAM) patients. Median duration between hospital discharge for COVID-19 to re-admission for Mucormycosis was 7 (IQR: 2.5, 15.5) days. Twenty patients (33.9 %) were diagnosed to have Mucormycosis (suspected fungal sinusitis, ROCM) during admission for COVID-19. Twenty-seven (45.7 %) were re-admitted less than 14 days after hospital discharge for COVID-19 while 12 (20.4 %) were re-admitted after more than 14 days. Headache (43/58, 74.1 %), hemi-facial pain predominantly maxillary pain (42/58, 72.4 %) and facial swelling (33/58, 56.9 %) were the three commonest presenting symptoms of ROCM in our cohort (Table 3). Median duration of symptoms was 6 (IQR: 3, 8.5) days. Seven patients (11.9 %) had symptoms for more than 2 weeks prior to diagnosis of ROCM. Fifty-eight patients (99%) had rhinal (paranasal sinus) involvement, 33 (56%) had orbital (eyeball, extra-ocular muscles or orbital cavity) and 26 (44.1%) had cerebral involvement (infarcts, cavernous sinus involvement, dural enhancement, frontal lobe abscess, osteomyelitis and erosion of frontal bone, Table 3). Palatal involvement (palatal necrosis, black eschar or palatal osteomyelitis) was observed in 13 (22 %) patients. Median hemoglobin value at diagnosis of Mucormycosis was 13.4 (IQR: 11.4, 14.5) mg/dl (Table 4). Median absolute neutrophil count (ANC) was 8100 (IQR: 5248, 11475) cells/mm3 and median absolute lymphocyte count (ALC) was 1350 (IQR: 1010, 1750) cells/mm3. Fourteen patients (24.6 %) had ALC < 1000 cells/mm3 while no patient had ANC < 1000 cells/mm3 at admission. Median CRP at admission was 84.7 (IQR: 41,167, 45 patients) mg/L, median D-dimer was 483.5 (IQR: 253.7,1201, 37 patients) mcg/mL, and median Ferritin value was 857.1 (IQR: 280.5, 1429, 32 patients) mcg/L. Thirteen patients (40.6 %) had serum Ferritin level > 1000 mcg/L at admission while 11 patients had D-dimer > 1000 mcg/mL. Median HbA1C level in our cohort was 9.3 (IQR: 8, 12). Ten patients (10/53, 18.9%) presented with diabetic ketoacidosis. Diagnosis of Mucormycosis was made by KOH/calcofluor white staining of nasal scrapings (25/59, 42.4%), culture (5/59, 8.5%) and histopathologic examination of excised tissue from paranasal sinuses (57/59, 96.6%). Mixed mould infection (mucormycosis and aspergillosis) was observed in 3 patients.

View this table:
[Table 3:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T4)

Table 3: Baseline characteristics of patients of Mucormycosis

View this table:
[Table 4:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T5)

Table 4: Baseline investigations during admission for Mucormycosis

Aggressive surgical debridement of involved site and combination antifungal therapy was standard of care for all ROCM patients in our cohort. Empirical combination anti-fungal therapy was started after radiologic evidence of invasive sinusitis, pending confirmatory diagnosis by histopathology or culture. Various treatment modalities used in our cohort are mentioned in Table 5. Intravenous (IV) formulations of Amphotericin B (Liposomal, Lipid-complex, Lipid emulsion or Deoxycholate) were the mainstay of antifungal therapy and prescribed to 91.5% (54/59) patients. In view of shortage of Liposomal Amphotericin B in India during the second COVID-19 wave, patients ended up getting a combination of Amphotericin B formulations as per availability. Liposomal Amphotericin B was prescribed to 89.8 % (53/59) patients for a median duration of 15 (IQR: 11, 21) days. Amphotericin B de-oxycholate or Conventional Amphotericin B was prescribed to 45.8% (27/59) patients for a median duration of 4 (IQR: 3, 9) days. The median duration of Amphotericin B exposure to patients in our cohort was 21 (IQR: 14, 27) days. All patients were also prescribed concomitant oral triazole therapy (Posaconazole (58/59, 98.3%) or Isavuconazole (5/59, 8.5%)) during admission and after discharge till clinician was satisfied about local control of disease. Median duration for oral triazole therapy was 60 days. FESS with orbital decompression was performed on 94.9 % patients (56/59). Surgical exenteration of the eye with debridement of orbital cavity was performed in 13 (22 %) patients. Partial maxillectomy was performed in 9 (15.3 %) patients while Neurosurgery for frontal lobebrain abscess drainage was performed in 5 (8.5 %) patients. Eight patients (13.6 %) required invasive mechanical ventilation while 18 (30.5 %) required ICU admission for Mucormycosis.

View this table:
[Table 5:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T6)

Table 5: Treatment regimens used in Mucormycosis

Complications during antifungal therapy and hospital admission are mentioned in Table 6. Fever with chills (78 %), Thrombophlebitis (59.3 %), Hypokalemia (88.1 %), Anemia (57.6 %) and Nephrotoxicity (50.8 %) were the most common complications observed during hospital admission. Central nervous system (CNS) complications (stroke/cerebritis/brain abscess) were seen in 25.4 % patients. There were 14 deaths (23.7 %) in our cohort during first hospital admission for Mucormycosis. On Relative risk analysis, CT severity score during COVID-19 admission ≥ 18 (p = 0.017), presence of symptoms like eye swelling (p = 0.002), loss of vision (p< 0.0001), ptosis (p = 0.005) and limb weakness (p = 0.001), presence of diabetic ketoacidosis (p = 0.011), cerebral involvement by Mucor (p = 0.0004) and development of CNS complications like stroke (p < 0.0001) during antifungal therapy were associated with increased risk of death (Table 7, Figure 1). Duration of Amphotericin B treatment of more than 21 days was associated with decreased risk of death (p = 0.002) on Relative risk analysis (Table 7). All patients who were discharged from hospital were followed up for a minimum period of 6 weeks to look for late complications. Three patients needed re-admission, 48, 54 and 37 days after first discharge in view of re-appearance of symptoms and/or imaging evidence of progression of disease to the CNS. All 3 patients needed repeat surgical debridement and additional Amphotericin B treatment. They were successfully discharged the second time. Two patients also needed re-admission for osteomyelitis of maxilla and alveolar arch which needed partial maxillectomy and placement of dental prosthesis. One patient who had undergone exentration of eye was readmitted 90 days later for insertion of orbital prosthesis. One patient who had been treated for cerebral mucormycosis (bilateral complete vision loss and multiple cerebral infarcts) with 42 days of high dose Liposomal Amphotericin B and Posaconazole was readmitted with aspiration pneumonia 12 days later and died. Cause of death was respiratory failure due to aspiration pneumonia and acute respiratory distress syndrome (ARDS, Total deaths in cohort - 15, 25.4%).

View this table:
[Table 6:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T7)

Table 6: Complications in Mucormycosis patients during antifungal therapy

View this table:
[Table 7:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/T8)

Table 7: Relative risk of death in Mucormycosis patients

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/09/22/2021.09.15.21263622/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622/F1)

Figure 1: 
Prevalence of risk factors in Mucormycosis patients who died

## Discussion

We conducted a single-centre, retrospective cohort study of 59 patients with CAM who were admitted at NHRC in the last 15 months. 74.6% patients could be successfully discharged after control of disease with combined surgical and medical approach. Mortality rate in our cohort at 6 weeks follow-up was 25.4 %.

Majority of the patients in our study were middle-aged (median age: 52□years), of which nearly two-thirds were male. It has been hypothesized that the effect of estrogen might be protective in systemic fungal infection, which could have led to lower incidence in females [68]. Case series on CAM by Sharma et al [46], described diabetes as a risk factor in 90% cases of which 52% had uncontrolled disease. A systematic review of 101 cases of CAM by Singh et al [58] also noted that more than 80% cases had either pre-existing or new onset hyperglycaemia as a risk factor. Our study has demonstrated similar findings in that 90 % of included patients were diabetic with almost 30% being newly diagnosed with DM at the time of admission for COVID-Of the 56 patients who had HbA1c value available, 50 had uncontrolled DM (HbA1c > 7%). Median HbA1c in our cohort was 9.3% while it was 9.6% in the study by Sen et al [55]. Tight control of blood sugar level among patients with Diabetes Mellitus/ COVID-19 co-infection could help in reducing incidence of ROCM.

Both the RECOVERY trial [17] and WHO COVID-19 [69] guidelines clearly recommend against usage of Corticosteroids in COVID-19 patients not requiring oxygen (absence of hypoxia). Despite that, indiscriminate use of steroids in mild COVID-19 continues in India. The underlying reasons include the sudden surge of cases during second COVID wave leading to panic among general practitioners, inadequate time for triaging patients in busy outpatient clinics, non evidence-based clinical practice, availability of over the counter steroids, shortage of hospital beds and inadequate monitoring of the patients taking steroids. The improper use of corticosteroids has been identified as an independent risk factor for CAM by the MucoCovi network [7]. In their retrospective analysis of 187 Indian CAM patients, they found that 78% (150/187) had received steroid therapy but only 33% patients had received steroids at appropriate dosages. In 33 % patients (50/150), steroids were not indicated while among 30% (45/150) patients steroids were indicated but were prescribed in inappropriately high dose [7]. In comparison, in our study, 56 % patients were prescribed steroids for non-hypoxemic, mild to moderate COVID illness (irrational steroid therapy) while in 8.5 % patients steroids were indicated but were prescribed in inappropriately high dose. Thus there is an urgent need to stop prescription of steroids in non-hypoxemic COVID-19 patients and to limit the dose and duration of steroids in hypoxic patients.

In our cohort, majority of the patients were treated with a combination of surgical debridement (94%) and intravenous Amphotericin B therapy (91%). Mortality rate at 6 weeks follow-up was 25.4 % which is lower than what is reported by Pal et al [57] and Patel et al (MucoCovi network - 6 week mortality rate of 38.3 % and 12 week mortality of 45.7 %) [7]. Reasons for lower mortality in our cohort as compared to the MucoCovi network [7] could be relatively younger population (median age 52 years versus 56.9 years), lower prevalence of hypoxia during COVID-19 (44 % versus 56 %), lower pulmonary involvement due to Mucormycosis (0 % versus 8.6 %), increased use of combination antifungal therapy (91% versus 50%) and higher use of combined surgical and medical approach (91% versus 71%). However, presence of diabetic ketoacidosis (10.9 % versus 8.6 %) and prevalence of cerebral involvement due to Mucor (44 % versus 23 %) was higher in our cohort than the MucoCovi study [7]. Both the factors, presence of diabetic ketoacidosis (p = 0.011) and cerebral involvement with Mucor (p = 0.0004) were associated with higher risk of mortality on Relative risk analysis. In patients with cerebral involvement due to Mucor, mortality rate was 50% which is 5 times higher than among patients without cerebral involvement. On the other hand, duration of Amphotericin B therapy of more than 21 days was associated with statistically significant reduction in mortality (p = 0.002). Development of ROCM while the patient is still under active treatment for moderate or severe COVID-19 may pose significant challenges in the management – specifically termination of corticosteroids, and surgery under general anesthesia. This was reflected in the CT severity index > 18 (depicting severe COVID pneumonia) being a significant risk factor for increased risk of death due to CAM (p = 0.017). Patients with ROCM also remain at risk for delayed complications and may need re-admission with further surgical and anti-fungal treatment to resolve them.

### Limitations

Our study has several limitations. First, this is not a randomized controlled trial, and therefore unmeasured confounding cannot be ruled out. Second, as for all retrospective studies, some individuals diagnosed with Mucormycosis may be unreported leading to measurement bias and underestimation of mortality due to CAM. Third, we collected data from a single centre in India unlike other multicenter cohort studies [7, 52,54,55,57]. Fourth, an overwhelmed health care system, inadequate workforce and lack of exhaustive reporting due to surge of cases during second COVID wave could be responsible for underestimation of co-morbidities, presenting symptoms and complications amongst patients in our cohort. Fifth, inflammatory markers like Ferritin, CRP and D-dimer were not available for all patients in the cohort. Sixth, we did not look for environmental factors causing healthcare-associated mucormycosis like contaminated ventilation systems, air conditioners, and ongoing construction in our hospital. We did not estimate the burden of Mucormycetes spores in our hospital environment. We also didn’t investigate the link between risk factors like use of industrial oxygen during the COVID pandemic, contaminated nebulizer fluids or inline humidifier tubing used in ventilator circuits and contaminated oxygen delivery systems with increased incidence of CAM in our cohort [10]. Seventh, other unexplored factors, including genetic predisposition were not identified.

Despite these limitations, this retrospective cohort study adds to the growing body of literature on epidemiology, management strategies, outcomes and long term complications due to COVID-19 associated Mucormycosis (CAM).

## Conclusions

COVID-19 associated Mucormycosis (CAM) is an uncommon, rapidly progressive, angio-invasive, opportunistic fungal infection which is fatal if left untreated. The most common form of CAM seen in our cohort was the Rhino-orbito-cerebral (ROCM) one. COVID-19 induced immune dysregulation, uncontrolled diabetes mellitus and indiscriminate use of steroids may be the risk factors associated with the sudden surge in Mucormycosis cases in India during the second wave. Clinicians should have a high index of suspicion for ROCM in patients recovering from COVID-19, especially among patients with new or previously diagnosed diabetes mellitus and clinical manifestations of headache, facial or orbital pain. Combination of surgical debridement and intravenous Amphotericin B therapy leads to clinical and radiologic improvement in majority of cases. Cerebral involvement by Mucor is associated with higher mortality.

## Data Availability

All data related to the manuscript is available at Figshare

[https://figshare.com/s/b96305da2644d4b3de12](https://figshare.com/s/b96305da2644d4b3de12) 

## Acknowledgements

Manisha Ghate MD, PhD (National AIDS Research Institute (NARI), Pune, India) - edited the manuscript.

## Footnotes

*   **Email addresses of authors:** Reema Kashiva – reemakashiva{at}gmail.com, Zafer Khan – zafer\_a\_khan{at}yahoo.co.in, Balasaheb Bande – drbandebd{at}hotmail.com, Danish Memon – danish1331{at}yahoo.co.in, Aparna Kodre – draparnankodre{at}gmail.com, Prashant Potdar – pashya2511{at}gmail.com, Milind Mane – drmilind.mane{at}gmail.com, Asir Tamboli – drasirtamboli{at}gmail.com, Vishal Pawar – dr.vishal.d.pawar{at}gmail.com, Dattatraya Patil – drdattapatil05{at}gmail.com, Debashis Banerjee – debaz2009{at}gmail.com, Kailas Bhoite – kailasbhoite1978{at}gmail.com, Akshay Shinde – dr.akshay7{at}gmail.com, Reshma Pharande – reshma.pharande97{at}gmail.com, Suraj Kalyani – surajkalyani{at}gmail.com, Prathamesh Raut – raut1esh{at}gmail.com, Madhura Bapte – madhuraparth{at}gmail.com, Charlotte Saldanha – charlotte2491{at}gmail.com, Dinesh Chandak – dineshchandak444{at}gmail.com, Fouzia Ajani – drfouziahirani{at}gmail.com, Anshul Mehta – anshroks.25{at}gmail.com, M Sateesh Reddy – satishat321{at}gmail.com, Krushnadas Bhayani – kbhayani321{at}gmail.com, S S Laxmi – drsslakshmiatl{at}gmail.com, P D Vishnu – p.d_vishnu{at}yahoo.co.in, Shipra Srivastava – srivastavashipra51{at}gmail.com, Shubham Khandelwal – shubh.joyrider{at}gmail.com, Sailee More – drsaileemore{at}gmail.com, Atif Shakeel – khanaatif009{at}gmail.com, Mohit Pawar – mohitpawar2915{at}gmail.com, Pranava Nande – pranavanande4{at}gmail.com, Amol Harshe – dramolh{at}yahoo.co.in, Sagar Kadam – drsagarkadam{at}gmail.com, Sudhir Halikar – halikarsudhir{at}gmail.com, Nudrat Kamal- nudratkamal86{at}gmail.com, Danish Andrabi – danish_andrabi{at}yahoo.co.in, Sachin Bodhale – drsrb1{at}gmail.com, Akshay Raut – akshayraut8{at}gmail.com, Pushkar Gawande – gawandepushkar{at}gmail.com, Ankush Bhandari – dr.ankushbhandari{at}yahoo.com, Nilesh Wasmatkar – drnileshkw{at}gmail.com, Adnanali Sarkar – adnansarkar2{at}gmail.com, Sangeeta Chandrashekhar – drsangeet15{at}rediffmail.com, Pallavi Butiyani – pallavibutiyani{at}gmail.com, Geetanjali Akhade – dangat.geeta{at}gmail.com, Aditi Abnave – abnaveaditi{at}gmail.com, Chandrashekhar Raman – drshekhar71{at}hotmail.com, Siraj Basade - siraj582{at}yahoo.com, Uma Mahajan – umasmahajan{at}gmail.com, Gaurav Joshi – gaurav.arun.joshi{at}gmail.com, Dilip Mane – dileep.mane{at}yahoo.co.in.

## Abbreviations

SARS-CoV-2
:   Severe acute respiratory syndrome coronavirus 2
COVID-19
:   coronavirus disease 2019
WHO
:   World health organization
CAM
:   COVID-19 associated Mucormycosis
CRP
:   C-reactive protein
LDH
:   lactate dehydrogenase
IL-6
:   Interleukin - 6
IFN-γ
:   Interferon Gamma
DM
:   diabetes mellitus
TCZ
:   Tocilizumab
CRS
:   cytokine release syndrome
DKA
:   diabetic ketoacidosis
ROCM
:   Rhino-orbito-cerebral mucormycosis
NHRC
:   Noble hospital and Research Centre
HRCT
:   High resolution computerized tomography scan
SpO2
:   oxygen saturation
PaO2/FiO2;
:   ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
FESS
:   Functional endoscopic paranasal sinus surgery
LAm B
:   Liposomal Amphotericin B
RT-PCR
:   reverse transcription PCR
ICU
:   Intensive care unit
CNS
:   Central nervous system
IRB
:   institutional review board
IQR
:   interquartile range
ANC
:   absolute neutrophil count
ALC
:   absolute lymphocyte count
IV
:   Intravenous
ARDS
:   acute respiratory distress syndrome

*   Received September 15, 2021.
*   Revision received September 15, 2021.
*   Accepted September 22, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1).Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. [https://doi.org/10.1001/jama.2020.2648](https://doi.org/10.1001/jama.2020.2648)
    
    

2.  2).World health organization (WHO): Available at [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it).
    
    

3.  3).World health organization (WHO) Coronavirus disease (COVID-19) dashboard. Available at: [https://covid19.who.int](https://covid19.who.int).
    
    

4.  4).Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3; 71(9):2459–2468. doi: 10.1093/cid/ciaa530. PMID: 32358954; PMCID: PMC7197596.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciaa530&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

5.  5).Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020 Aug; 185(4):599–606. doi: 10.1007/s11046-020-00462-9. Epub 2020 Jul 31. PMID: 32737747; PMCID: PMC7394275.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11046-020-00462-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

6.  6).Press release from Government of India at [https://pib.gov.in/PressReleasePage.aspx?PRID=1728153](https://pib.gov.in/PressReleasePage.aspx?PRID=1728153) accessed July 21st, 2021.
    
    

7.  7).Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R et al; MucoCovi Network3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis. 2021 Jun 4; 27 (9). doi: 10.3201/eid2709.210934. Epub ahead of print. PMID: 34087089.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3201/eid2709.210934&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34087089&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

8.  8).Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care. 2019 Jun; 51:64–70. doi: 10.1016/j.jcrc.2019.02.005. Epub 2019 Feb 5. PMID: 30769292.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jcrc.2019.02.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30769292&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

9.  9).Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019 Mar 21; 5(1):26.
    
    

10. 10).Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease. Clin Infect Dis. 2021 Aug 22:ciab726. doi: 10.1093/cid/ciab726. Epub ahead of print. PMID: 34420052.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciab726&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34420052&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

11. 11).García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020 Jun 16; 11: 1441. [https://doi.org/10.3389/fimmu.2020.01441](https://doi.org/10.3389/fimmu.2020.01441)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fimmu.2020.01441&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

12. 12).Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020 May 29; 5(1):84. [https://doi.org/10.1038/s41392-020-0191-1](https://doi.org/10.1038/s41392-020-0191-1)
    
    

13. 13).IDF Diabetes ATLAS Ninth Edition. 2019. https://diabetesatlas.org/pload/resources/material/20200302\_133351\_IDFATLAS9e–final-web.pdf#page=42&zoom=auto. accessed May 12, 2020.
    
    

14. 14).Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states : results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5: 585–596.
    
    

15. 15).Müller JA, Groß R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021; 3: 149–165. [https://doi.org/10.1038/s42255-021-00347-1](https://doi.org/10.1038/s42255-021-00347-1).
    
    

16. 16).WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6; 324(13):1330–1341. [https://doi.org/10.1001/jama.2020.17023](https://doi.org/10.1001/jama.2020.17023)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.17023&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

17. 17).RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med. 2020 Jul 17: NEJMoa2021436. [https://doi.org/10.1056/NEJMoa2021436](https://doi.org/10.1056/NEJMoa2021436)
    
    

18. 18).Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003 Nov 29;362(9398):1828–38. doi: 10.1016/S0140-6736(03)14904-5. PMID: 14654323.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(03)14904-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14654323&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000186872900024&link_type=ISI) 

19. 19).Rodriguez-Morales AJ, Sah R, Millan-Oñate J, Gonzalez A, Montenegro-Idrogo JJ, Scherger S et al. COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis. 2021 Jun 18;8: 20499361211027065. doi: 10.1177/20499361211027065. PMID: 34211710; PMCID: PMC8216396.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/20499361211027065&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34211710&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

20. 20).Actemra (tocilizumab) Prescribing information. South San Francisco, CA: Genentech, Inc; 2019.
    
    

21. 21).Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008; 21: 620–625. [https://doi.org/10.1097/QCO.0b013e3283\_165fd1](https://doi.org/10.1097/QCO.0b013e3283_165fd1)
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/QCO.0b013e3283165fd1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18978530&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000261387200007&link_type=ISI) 

22. 22).Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020; 68 : 213–224. [https://doi.org/10.1007/s12026-020-09145-5](https://doi.org/10.1007/s12026-020-09145-5).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12026-020-09145-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32681497&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

23. 23).Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A, Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020 Dec 17:1–6. doi: 10.1007/s15010-020-01561-x. Epub ahead of print. PMID: 33331988; PMCID: PMC7745708.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s15010-020-01561-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33331988&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

24. 24).Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020; 53: 746–749.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

25. 25).Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. Medicina. 2019;55: 1–14.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

26. 26).Brunet K and Rammaert B. Mucormycosis treatment: recommendations, latest advances, and perspectives. J Mycol Med 2020; 30: 101007.
    
    

27. 27).Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021 May;186(2):289–298. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 33544266; PMCID: PMC7862973.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11046-021-00528-2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33544266&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

28. 28).Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID-19 patient. BMJ Case Rep. 2021 Jun 24;14(6):e244232. doi: 10.1136/bcr-2021-244232. PMID: 34167998; PMCID: PMC8230977.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1136/bcr-2021-244232&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34167998&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

29. 29).Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features. Indian J Ophthalmol. 2021 Jun;69(6):1627–1630. doi: 10.4103/ijo.IJO\_1053\_21. PMID: 34011758.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijo.IJO_1053_21&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34011758&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

30. 30).Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264.e5–264.e8.
    
    

31. 31).Placik DA, Taylor WL and Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep 2020; 15: 2378–2381.
    
    

32. 32).Kanwar A, Jordan A, Olewiler S, et al. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi (Basel) 2021; 7: 174.
    
    

33. 33).Dallalzadeh LO, Ozzello DJ, Liu CY, et al. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. Epub ahead of print 23 March 2021. DOI: 10.1080/01676830.2021.1903044.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/01676830.2021.1903044&link_type=DOI) 

34. 34).Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021; 32: 64–67.
    
    

35. 35).Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel) 2021; 7: 88.
    
    

36. 36).Khatri A, Chang KM, Berlinrut I, et al. Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient – case report and review of literature. J Mycol Med 2021; 31: 101125.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

37. 37).Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19. Cureus. 2021 Feb 5;13(2):e13163. doi: 10.7759/cureus.13163. PMID: 33575155; PMCID: PMC7870113.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7759/cureus.13163&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33575155&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

38. 38).Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARSCoV-2) patient. Infect Dis Now. Epub ahead of print 27 January 2021. DOI: 10.1016/j.idnow.2021.01.010.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.idnow.2021.01.010&link_type=DOI) 

39. 39).Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. Epub ahead of print 16 February 2021. DOI: 10.1111/myc.13256.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/myc.13256&link_type=DOI) 

40. 40).Karimi-Galougahi M, Arastou S and Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. Epub ahead of print 13 March 2021. DOI: 10.1002/alr.22785.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/alr.22785&link_type=DOI) 

41. 41).Veisi A, Bagheri A, Eshaghi M, et al. Rhinoorbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. Epub ahead of print 10 April 2021. DOI: 10.1177/11206721211009450.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/11206721211009450&link_type=DOI) 

42. 42).Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: A lethal complication in follow-up. Transpl Infect Dis. 2021. June 3:e13663. [https://doi.org/10.1111/tid.1366310.1111/tid.13663](https://doi.org/10.1111/tid.1366310.1111/tid.13663) PMID: ;PMCID:. - DOI - PMC -PubMed
    
    

43. 43).Mehta S and Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020; 12: e10726.
    
    

44. 44).Sen M, Lahane S, Lahane TP, et al. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 2021; 69: 244–252.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

45. 45).Sarkar S, Gokhale T, Choudhury SS, et al. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69: 1002–1004.
    
    

46. 46).Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. Epub ahead of print 8 April 2021. DOI: 10.1017/S0022215121000992.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S0022215121000992&link_type=DOI) 

47. 47).Saldanha M, Reddy R,Vincent MJ. Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg. Epub ahead of print 22 April 2021. doi: 10.1007/s12070-021-02574-0.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12070-021-02574-0&link_type=DOI) 

48. 48).Revannavar SM, Supriya PS, Samaga L, et al. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021; 14: e241663.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToiYm1qY3IiO3M6NToicmVzaWQiO3M6MTI6IjE0LzQvZTI0MTY2MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzA5LzIyLzIwMjEuMDkuMTUuMjEyNjM2MjIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

49. 49).Maini A, Tomar G, Khanna D, et al. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep 2021; 82: 105957.
    
    

50. 50).Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases. 2021;25:e01172. doi: 10.1016/j.idcr.2021.e01172. Epub 2021 May 28. PMID: 34075329; PMCID: PMC8161734.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.idcr.2021.e01172&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34075329&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

51. 51).Ravani SA, Agrawal GA, Leuva PA, et al. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69: 1563–1568
    
    

52. 52).Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021 Jul 13. doi: 10.1111/myc.13353. Epub ahead of print. PMID: 34255907.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/myc.13353&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34255907&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

53. 53).Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. Epub ahead of print 6 March 2021. DOI: 10.1007/s12663-021-01532-1.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12663-021-01532-1&link_type=DOI) 

54. 54).Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, Barac A, Abdollahi A, Khodavaisy S. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021 Jun 7:10.1111/myc.13334. doi: 10.1111/myc.13334. Epub ahead of print. PMID: 34096653; PMCID: PMC8242414.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/myc.13334&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34096653&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

55. 55).Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021;69 (7):1670–1692. doi:10.4103/ijo.IJO\_1565\_21.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijo.IJO_1565_21&link_type=DOI) 

56. 56).Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D et al. COVID-19 associated Mucormycosis Presenting to the Emergency Department - An Observational Study of 70 Patients. QJM. 2021 Jul 12: hcab190. doi: 10.1093/qjmed/hcab190. Epub ahead of print. PMID: 34254132.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/qjmed/hcab190&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34254132&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

57. 57).Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021 Jun 16. doi: 10.1111/myc.13338. Epub ahead of print. PMID: 34133798.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/myc.13338&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34133798&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

58. 58).Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15 (4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub ahead of print. PMID: 34192610; PMCID: PMC8137376.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.dsx.2021.05.019&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

59. 59).Mishra Y, Prashar M, Sharma D, Akash Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr. 2021 Jul 3;15 (4):102196. doi: 10.1016/j.dsx.2021.102196. Epub ahead of print. PMID: 34246939; PMCID: PMC8253699.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.dsx.2021.102196&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34246939&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

60. 60).Kumari A, Rao NP, Patnaik U, Malik V, Tevatia MS, Thakur S et al. Management outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary care hospital. Med J Armed Forces India. 2021 Jul;77: S289–S295. doi: 10.1016/j.mjafi.2021.06.009. Epub 2021 Jul 26. PMID: 34334896; PMCID: PMC8313063.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.mjafi.2021.06.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34334896&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

61. 61).Dubey S, Mukherjee D, Sarkar P, Mukhopadhyay P, Barman D, Bandopadhyay M et al. COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab Syndr. 2021 Sep 1:102267. doi: 10.1016/j.dsx.2021.102267. Epub ahead of print. PMCID: PMC8407938.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.dsx.2021.102267&link_type=DOI) 

62. 62).CLINICAL MANAGEMENT PROTOCOL: COVID-19. Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division). Version 5. Published May 2021. Available at: [https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf](https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf).
    
    

63. 63).Guideline for management of Mucormycosis in Covid – 19 patients. Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division). Available at: [https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf](https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf)
    
    

64. 64).Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19: e405–e421.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

65. 65).Shah K, Dave V, Bradoo R, Shinde C, Prathibha M. Orbital Exenteration in Rhino-Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring System. Indian J Otolaryngol Head Neck Surg. 2019; 71 (2):259–265. doi:10.1007/s12070-018-1293-8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12070-018-1293-8&link_type=DOI) 

66. 66).Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020 Dec; 30(12): 6808–6817. [https://doi.org/10.1007/s00330-020-07033-y](https://doi.org/10.1007/s00330-020-07033-y).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 

67. 67).AIIMS/ICMR-COVID-19 National Task force/Joint monitoring group (Dte GHS). Ministry of health and family welfare, Government of India. Clinical guidance for management of adult COVID-19 patients. Published 17th May 2021. Available at: [https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/](https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/)
    
    

68. 68).Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1; 41(5):634–53. doi: 10.1086/432579. Epub 2005 Jul 29. PMID: 16080086.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/432579&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16080086&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F09%2F22%2F2021.09.15.21263622.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000230995600010&link_type=ISI) 

69. 69).World health organization (WHO): COVID-19 Clinical management: living guidance. Accessed 1st September 2021. Available at: [https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1](https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1)